Compare Carvana Co (CVNA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs TransMedics Group Inc — how do they compare? Carvana Co trades at $63.73 (market cap $69.55B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Carvana Co is far larger — about 25.4× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 7,671,750). Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and TransMedics Group Inc for 24 Days on average.
| CVNA | TMDX | |
|---|---|---|
Market Cap | $69.55B | $2.74B |
Volume | 7,671,750 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $150.42 |
52-Week Low | $56.27 | $61.99 |
Typical Hold Time | 28 Days | 24 Days |
Enterprise Value | $72.04B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, up 0.72% with strong fundamental momentum including 10 consecutive quarters of record profitability. Revenue surged 52% in Q2 FY26 to $20.32B annually, while net income reached $1.41B with a 6.26% margin. Technical indicators show bearish momentum with key support at $61-62, though RSI levels remain neutral. The company continues expanding capacity to meet robust demand, with same-day delivery recently launched in Minneapolis.
CVNA presents growth potential with analyst consensus target of $84.07 (33% upside), but faces risks from high debt levels ($5.26B long-term) and volatile cash flow patterns. The stock's elevated P/E of 33.44 and EV/EBITDA of 507.31 suggest premium valuation, requiring sustained execution to justify. Competitive pressures in online auto retail and interest rate sensitivity remain key watchpoints for investors.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
